Literature DB >> 7017566

Studies on group B beta-hemolytic Streptococcus. II. Effects on pulmonary hemodynamics and vascular permeability in unanesthetized sheep.

J Rojas, R S Green, C G Hellerqvist, R Olegard, K L Brigham, M T Stahlman.   

Abstract

To study the effects of Group B beta-hemolytic Streptococcus on the pulmonary circulation and lung fluid balance, live and heat-killed bacteria and their toxin were infused into an awake sheep lung-lymph preparation. In every case, the response was biphasic; there was an initial period of marked pulmonary hypertension and high flow of protein-poor lymph associated with tachypnea, chills, and fever. A second phase followed during which pulmonary vascular pressures returned to near baseline and remained stable, but lymph flow remained high. The changes seen in the initial phase resemble the previously reported response to mechanically increased pulmonary vascular pressure and suggest that the increase in fluid filtration is secondary to increased microvascular pressure. During the second phase after toxin infusion, the increase in lung lymph flow was paralleled by an increase in lymph protein clearance. This cannot be accounted for by the hemodynamic changes alone an suggests that the permeability of lung microvascular walls to protein was increased. It is concluded that group B beta-hemolytic streptococcal toxin in the sheep model causes pulmonary hypertension and increased pulmonary vascular permeability.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017566     DOI: 10.1203/00006450-198106000-00003

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  15 in total

Review 1.  Treatment of persistent pulmonary hypertension of the newborn: update.

Authors:  Y K Abu-Osba
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

2.  Fatal ureaplasmal pneumonia and sepsis in a newborn infant.

Authors:  F Brus; W M van Waarde; C Schoots; S B Oetomo
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

3.  Group B Streptococcus impairs erythrocyte deformability in neonates more than in adults.

Authors:  J M Pöschl; P Ruef; M Schnauffer; S Pohl; H G Sonntag; O Linderkamp
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-05       Impact factor: 5.747

Review 4.  Group B Streptococcus, phospholipids and pulmonary hypertension.

Authors:  J Curtis; G Kim; N B Wehr; R L Levine
Journal:  J Perinatol       Date:  2011-04       Impact factor: 2.521

5.  Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin).

Authors:  G B Thurman; D L Page; B D Wamil; L E Wilkinson; M Kasami; C G Hellerqvist
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Group B streptococcal phospholipid causes pulmonary hypertension.

Authors:  Jerri Curtis; Geumsoo Kim; Nancy B Wehr; Rodney L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

7.  Group B streptococci (GBS) injure lung endothelium in vitro: GBS invasion and GBS-induced eicosanoid production is greater with microvascular than with pulmonary artery cells.

Authors:  R L Gibson; C Soderland; W R Henderson; E Y Chi; C E Rubens
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus.

Authors:  C G Hellerqvist; G B Thurman; D L Page; Y F Wang; B A Russell; C A Montgomery; H W Sundell
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Molecular basis for group B beta-hemolytic streptococcal disease.

Authors:  C G Hellerqvist; H Sundell; P Gettins
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.

Authors:  J F Bohnsack; J K Chang; H R Hill
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.